This led us to propose that a vaccine which would be constituted by multi-founder like, minimally distant antigens (differing by ~1% in Env) corresponding to the variability we observed in infections with multiple founder variants could initiate the induction of bnAbs. The gene discussed is ERVW-1; the disease is infection.